Dopamine, Cognitive Impairments and Second-Generation Antipsychotics: From Mechanistic Advances to More Personalized Treatments
The pharmacological treatment of cognitive impairments associated with schizophrenia is still a major unmet clinical need. Indeed, treatments with available antipsychotics generate highly variable cognitive responses among patients with schizophrenia. This has led to the general assumption that anti...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Artigo |
| Language: | Inglês |
| Published: |
MDPI AG
2020-11-01
|
| Series: | Pharmaceuticals |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1424-8247/13/11/365 |
| Tags: |
No Tags, Be the first to tag this record!
|
